In phase I of clinical trials, absorption, distribution, metabolism and excretion of an active compound is investigated (adme). In phase II, efficacy and safety in the target indication is established with up to several hundred patients (proof of concept). The final dosage is determined. Once the proof of concept has been confirmed, clinical trials with a large patient population confirm and refine safety and efficacy (phase III).
We deliver reference samples like metabolic derivatives, product impurities and precursors.